Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
emeraldhealth.ca

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

10

About Emerald Health Therapeutics

Emerald Health Therapeutics (CSE: EMH) is a Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. The company was founded in 2014 and is based in Victoria, British Columbia.

Emerald Health Therapeutics Headquarter Location

101 – 4226 Commerce Circle

Victoria, British Columbia, V8Z 6N6,

Canada

800-757-3536

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Emerald Health Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Emerald Health Therapeutics in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest Emerald Health Therapeutics News

Cannabis Stock News: Emerald Health Therapeutics, Inc. (CSE: EMH) Restates Q1 Financial Statements to Meet PCAOB Standard

Aug 12, 2022

Vancouver, British Columbia - August 12, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a) cash and cash equivalents (b) revenue from sale of goods and (c) impairment of assets. The Restatements were identified during a review conducted by MNP LLP ("MNP"), the Company's auditor, in accordance with the standards established by the Public Company Accounting Oversight Board (United States) ("PCAOB") to satisfy the requirements for inclusion of the Company's previously filed financial statements and management's discussion and analysis into the Skye Bioscience, Inc. ("Skye") proxy statement in Form 14A in connection with the previously announced arrangement involving the Company and Skye. Readers of the Restated Q1 Financial Statements and Restated MD&A should note that the Restatements do not materially change the Company's overall cash position, and do not impact the value of the Company's assets. A summary of the material Restatements is described below: certain cash payments had not previously been recognized and as a result, the Restatements include adjustments to reflect the proper application of cash payments received, decreasing the Company's cash balance as of March 31, 2022 by $111,000; previously unrecognized commission revenue was identified and pass-through sales were noted as not eliminated; as such, the Restatements include adjustments to reflect the proper elimination of pass-through sales and recognition of commission revenue, resulting in a decrease of $167,000 to accounts receivable in the unaudited condensed interim consolidated statement of cash flows for the three months ended March 31, 2022; and previously unidentified indicators of impairment for biological assets were noted and accordingly, the Restatements include adjustments to reflect the Company's assessment of impairment expense, resulting in a restatement of the balances of inventory write-down and changes in inventory and biological assets in the unaudited condensed interim consolidated statement of cash flows for the three months ended March 31, 2022 to reflect net adjustments of $771,000 and a decrease of $488,000, respectively. Further details of such matters together with a discussion of various other non-material restatements and adjustments can be found in Note 3 to the Restated Financial Statements and in the Restated M&A, both of which are available under the Company's profile on SEDAR at www.sedar.com. Please visit www.emeraldhealth.ca for more information or contact: Moe Jiwan, Chief Operating Officer 1(800) 757 3536 Ext. #5 Emerald Investor Relations

Emerald Health Therapeutics Investments

2 Investments

Emerald Health Therapeutics has made 2 investments. Their latest investment was in prima as part of their Seed VC - II on May 5, 2021.

CBI Logo

Emerald Health Therapeutics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/21/2021

Seed VC - II

prima

$9.2M

Yes

3

7/30/2018

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

5/21/2021

7/30/2018

Round

Seed VC - II

Corporate Minority

Company

prima

Subscribe to see more

Amount

$9.2M

New?

Yes

Subscribe to see more

Co-Investors

Sources

3

10

Emerald Health Therapeutics Portfolio Exits

1 Portfolio Exit

Emerald Health Therapeutics has 1 portfolio exit. Their latest portfolio exit was Pure Sunfarms on November 26, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/26/2019

Corporate Majority

$99M

1

Date

11/26/2019

Exit

Corporate Majority

Companies

Valuation

$99M

Acquirer

Sources

1

Emerald Health Therapeutics Acquisitions

4 Acquisitions

Emerald Health Therapeutics acquired 4 companies. Their latest acquisition was Northern Vine Labs on July 20, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/20/2018

$99M

Acquired

1

5/2/2018

Subscribe to see more

$99M

Subscribe to see more

10

5/1/2018

Subscribe to see more

$99M

Subscribe to see more

10

10/26/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2018

5/2/2018

5/1/2018

10/26/2017

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Emerald Health Therapeutics Partners & Customers

10 Partners and customers

Emerald Health Therapeutics has 10 strategic partners and customers. Emerald Health Therapeutics recently partnered with flowerpod on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/28/2021

Licensee

Cannabis Stock News: Emerald Health Therapeutics (CSE: EMH) Strategic Licensee, FlowerPod, Unveils Groundbreaking Dose-Controlled Cannabis Vaping Product, New Brand, and U.S. Launch Plans

Vancouver , British Columbia - October 28 , 2021 Emerald Health Therapeutics , Inc. announces that its partner , FlowerPod , has completed product development related to a new form of cannabis consumption , a first-of-its-kind cannabis vaporizer puck , created a new brand called HUUE ™ , and established a partnership with Grenco Science , the leader in advanced cannabis vaporization technology , to provide a go-to-market strategy .

1

10/28/2021

Licensee

Cannabis Stock News: Emerald Health Therapeutics (CSE: EMH) Strategic Licensee, FlowerPod, Unveils Groundbreaking Dose-Controlled Cannabis Vaping Product, New Brand, and U.S. Launch Plans

Vancouver , British Columbia - October 28 , 2021 Emerald Health Therapeutics , Inc. announces that its partner , FlowerPod , has completed product development related to a new form of cannabis consumption , a first-of-its-kind cannabis vaporizer puck , created a new brand called HUUE ™ , and established a partnership with Grenco Science , the leader in advanced cannabis vaporization technology , to provide a go-to-market strategy .

2

12/29/2020

Partner

Denmark

Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients

Vancouver , British Columbia -- -LRB- Newsfile Corp. - December 29 , 2020 -RRB- - Emerald Health Therapeutics , Inc. -LRB- Emerald Health Therapeutics , Inc. , Inc.TF -RRB- -LRB- `` Emerald Health Therapeutics , Inc. '' -RRB- today announced that its partner , STENOCARE , completed its first shipment and delivery of Emerald Health Therapeutics , Inc. medical cannabis oil to patients in Sweden .

2

12/23/2019

Client

Israel

Subscribe to see more

Subscribe to see more

10

12/23/2019

Vendor

Canada

Subscribe to see more

Subscribe to see more

10

Date

10/28/2021

10/28/2021

12/29/2020

12/23/2019

12/23/2019

Type

Licensee

Licensee

Partner

Client

Vendor

Business Partner

Country

Denmark

Israel

Canada

News Snippet

Cannabis Stock News: Emerald Health Therapeutics (CSE: EMH) Strategic Licensee, FlowerPod, Unveils Groundbreaking Dose-Controlled Cannabis Vaping Product, New Brand, and U.S. Launch Plans

Vancouver , British Columbia - October 28 , 2021 Emerald Health Therapeutics , Inc. announces that its partner , FlowerPod , has completed product development related to a new form of cannabis consumption , a first-of-its-kind cannabis vaporizer puck , created a new brand called HUUE ™ , and established a partnership with Grenco Science , the leader in advanced cannabis vaporization technology , to provide a go-to-market strategy .

Cannabis Stock News: Emerald Health Therapeutics (CSE: EMH) Strategic Licensee, FlowerPod, Unveils Groundbreaking Dose-Controlled Cannabis Vaping Product, New Brand, and U.S. Launch Plans

Vancouver , British Columbia - October 28 , 2021 Emerald Health Therapeutics , Inc. announces that its partner , FlowerPod , has completed product development related to a new form of cannabis consumption , a first-of-its-kind cannabis vaporizer puck , created a new brand called HUUE ™ , and established a partnership with Grenco Science , the leader in advanced cannabis vaporization technology , to provide a go-to-market strategy .

Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients

Vancouver , British Columbia -- -LRB- Newsfile Corp. - December 29 , 2020 -RRB- - Emerald Health Therapeutics , Inc. -LRB- Emerald Health Therapeutics , Inc. , Inc.TF -RRB- -LRB- `` Emerald Health Therapeutics , Inc. '' -RRB- today announced that its partner , STENOCARE , completed its first shipment and delivery of Emerald Health Therapeutics , Inc. medical cannabis oil to patients in Sweden .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Emerald Health Therapeutics Team

2 Team Members

Emerald Health Therapeutics has 2 team members, including former Chief Executive Officer, Chris Wagner.

Name

Work History

Title

Status

Chris Wagner

Chief Executive Officer

Former

Sean Rathbone MBA BMech

BDO Canada, Amazon, and Molson Coors

Chief Operating Officer

Former

Name

Chris Wagner

Sean Rathbone MBA BMech

Work History

BDO Canada, Amazon, and Molson Coors

Title

Chief Executive Officer

Chief Operating Officer

Status

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.